The Pharma Data

DECEMBER 13, 2020

.–( BUSINESS WIRE )– EdiGene, Inc. which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. He received his B.S.

Business Development 40

Business Development Development Gene Editing In-Vivo 40

Drug Discovery World

APRIL 17, 2024

DS: You say on your website that your approach is applicable to any disease where increasing protein expression is beneficial. What diseases are you currently targeting? JMB: Hundreds of genetic diseases involve a missing or deficient protein and/or enzyme. Can you give some examples?

Gene Expression 59

Gene Expression Gene Genetic Disease RNA 59

Pharmaceutical Technology

JULY 29, 2022

In order to find the specific RNA sequences for a genetic disease, the biotech is using an AI- and machine learning-based approach. In order to achieve these plans, CAMP 4’s CEO, Josh Mandel-Brehm stated the company will prioritise raising capital through partnerships and business development. Future Possibilities.

RNA 245

RNA Gene Expression Gene Gene Therapy 245

Drug Discovery World

AUGUST 28, 2023

Could it be possible to prevent genetic diseases? But we also want to develop autophagy agents for other diseases where the process is implicated, such as fibrotic diseases or even cardiovascular disease. DS: What’s next for the company’s pipeline?

Genetics 52

Genetics Protein Genetic Disease Clinical Trials 52

Pharmaceutical Technology

JUNE 19, 2023

Pharmaceutical companies are putting their trust in the immense potential this new generation of medicine has for treating individuals with rare genetic diseases, which currently affect an estimated 280 million patients worldwide. Cell and gene therapies are not your typical clinical supply chain.

Gene Therapy 130

Gene Therapy Gene Packaging Packaging 130

Drug Discovery World

JANUARY 30, 2024

Dr Naldini open new doors for cures for otherwise untreatable genetic diseases with the full impact of his work still untapped”, she said. Lentivirus strategies are one of the most widely used tools in biomedical research and clinical testing, says Stella Vnook, CEO, Likarda. “Dr

Gene Therapy 71

Gene Therapy Manufacturing Gene Clinical Trials 71

The Pharma Data

OCTOBER 15, 2020

The committee is tasked with supporting BeyondSpring’s business development activities related to its lead asset, Plinabulin, and other pipeline assets. Mukul Agarwal, former vice president of Corporate Development, at Forty Seven, Inc., BeyondSpring – BeyondSpring Inc. Sabbagh will replace David Thompson who is retiring.

In-Vivo 52

In-Vivo Business Development Manufacturing Development 52